|
rs387907158
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A nonsense mutation in PTPN11 (K99X), a pathogenic CCND1 splice site variant (P241P), a hotspot missense mutation in PIK3CA (E542K) and a hotspot missense mutation in TP53 (R249S); were observed in 25%, 75%, 30% and 40% of the HER2+ BC tissue samples, respectively.
|
30535550 |
2019 |
|
rs121913273
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A nonsense mutation in PTPN11 (K99X), a pathogenic CCND1 splice site variant (P241P), a hotspot missense mutation in PIK3CA (E542K) and a hotspot missense mutation in TP53 (R249S); were observed in 25%, 75%, 30% and 40% of the HER2+ BC tissue samples, respectively.
|
30535550 |
2019 |
|
rs186919241
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A nonsense mutation in PTPN11 (K99X), a pathogenic CCND1 splice site variant (P241P), a hotspot missense mutation in PIK3CA (E542K) and a hotspot missense mutation in TP53 (R249S); were observed in 25%, 75%, 30% and 40% of the HER2+ BC tissue samples, respectively.
|
30535550 |
2019 |
|
rs28933368
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A nonsense mutation in PTPN11 (K99X), a pathogenic CCND1 splice site variant (P241P), a hotspot missense mutation in PIK3CA (E542K) and a hotspot missense mutation in TP53 (R249S); were observed in 25%, 75%, 30% and 40% of the HER2+ BC tissue samples, respectively.
|
30535550 |
2019 |
|
rs28934571
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A nonsense mutation in PTPN11 (K99X), a pathogenic CCND1 splice site variant (P241P), a hotspot missense mutation in PIK3CA (E542K) and a hotspot missense mutation in TP53 (R249S); were observed in 25%, 75%, 30% and 40% of the HER2+ BC tissue samples, respectively.
|
30535550 |
2019 |
|
rs1045642
|
|
|
0.010 |
GeneticVariation |
BEFREE |
ABCB1 C3435T gene polymorphism as a potential biomarker of clinical outcomes in HER2-positive breast cancer patients.
|
27137881 |
2016 |
|
rs1045485
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Although hormone receptors and the molecular profile did not indicate any significant association with different genotypes (P > .05), patients with CC genotype of rs1045485 were more likely to have HER2-positive breast cancer than those with GG genotype (odds ratio [OR], 2.93; 95% confidence interval [CI], 1.0 4-8.26).
|
31362911 |
2019 |
|
rs1799864
|
|
|
0.010 |
GeneticVariation |
BEFREE |
CCR2-V64I genetic polymorphism: a possible involvement in HER2+ breast cancer.
|
25716470 |
2016 |
|
rs759478535
|
|
|
0.010 |
GeneticVariation |
BEFREE |
CCR2-V64I genetic polymorphism: a possible involvement in HER2+ breast cancer.
|
25716470 |
2016 |
|
rs763059810
|
|
|
0.010 |
GeneticVariation |
BEFREE |
CCR2-V64I genetic polymorphism: a possible involvement in HER2+ breast cancer.
|
25716470 |
2016 |
|
rs1058808
|
|
|
0.020 |
GeneticVariation |
BEFREE |
In a retrospective cohort study of 237 women with non-metastatic HER2-positive breast cancer treated with trastuzumab, traditional risk factors were assessed by review of medical records, alcohol use by an administered questionnaire to women (n=132), and HER2 polymorphisms (Ile655Val and Ala1170Pro) using TaqMan assays (n=73).
|
23749910 |
2013 |
|
rs121913279
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In the present study, we generated a compound mouse model that genetically mimics HER2-positive breast cancer with coexisting PIK3CA(H1047R).
|
26640141 |
2016 |
|
rs749539903
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In the present study, we generated a compound mouse model that genetically mimics HER2-positive breast cancer with coexisting PIK3CA(H1047R).
|
26640141 |
2016 |
|
rs166870
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In the two-stage GWAS stratified by tumor subtypes, rs166870 and rs10825036 were consistently associated with DFS in the HR+ HER2- and HR- HER2- breast cancer subtypes, respectively (Prs166870 = 2.88 × 10(-7) and Prs10825036 = 3.54 × 10(-7) in the combined set).
|
25867717 |
2015 |
|
rs10825036
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In the two-stage GWAS stratified by tumor subtypes, rs166870 and rs10825036 were consistently associated with DFS in the HR+ HER2- and HR- HER2- breast cancer subtypes, respectively (Prs166870 = 2.88 × 10(-7) and Prs10825036 = 3.54 × 10(-7) in the combined set).
|
25867717 |
2015 |
|
rs1136201
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Influence of the HER2 Ile655Val polymorphism on trastuzumab-induced cardiotoxicity in HER2-positive breast cancer patients: a meta-analysis.
|
26049584 |
2015 |
|
rs3746083
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Interestingly, by sequencing the entire TTP coding region in Hs578T cells that do not express the TTP protein, we identified a synonymous polymorphism (rs3746083) that showed a statistically significant association with a lack of response to Herceptin/Trastuzumab in HER2-positive-breast cancer patients.
|
21875902 |
2011 |
|
rs1442481831
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Of these, two mutations, the somatic mutations <i>ERBB4</i>-V721I and <i>ERBB4</i>-S303F, were stably transfected into HCC1954 (PIK3CA mutant), HCC1569 (PIK3CA wildtype) and BT474 (PIK3CA mutant, ER positive) HER2+ breast cancer cell lines for functional <i>in vitro</i> experiments.
|
30023006 |
2018 |
|
rs1484791833
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Of these, two mutations, the somatic mutations <i>ERBB4</i>-V721I and <i>ERBB4</i>-S303F, were stably transfected into HCC1954 (PIK3CA mutant), HCC1569 (PIK3CA wildtype) and BT474 (PIK3CA mutant, ER positive) HER2+ breast cancer cell lines for functional <i>in vitro</i> experiments.
|
30023006 |
2018 |
|
rs4919510
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Polymorphism rs4919510:C>G in mature sequence of human microRNA-608 contributes to the risk of HER2-positive breast cancer but not other subtypes.
|
22586447 |
2012 |
|
rs2293554
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Several SNPs were associated with all, ER-positive, and HER2-positive breast cancers; however, after correcting for multiple comparisons (i.e., p < 0.0008), only rs2293554 was statistically significantly associated with HER2-positive breast cancer (OR = 1.98, 95% CI 1.34-2.92, uncorrected p = 0.0005).
|
26758508 |
2016 |
|
rs1130214
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The A allele of <i>AKT1</i>:rs1130214 (OR, 2.095; <i>p</i>=0.011) and the C allele of <i>NQO2</i>:rs2071002 (OR, 1.632; <i>p</i>=0.045) were associated with HER2-positive breast cancer.
|
29963112 |
2018 |
|
rs2071002
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The A allele of <i>AKT1</i>:rs1130214 (OR, 2.095; <i>p</i>=0.011) and the C allele of <i>NQO2</i>:rs2071002 (OR, 1.632; <i>p</i>=0.045) were associated with HER2-positive breast cancer.
|
29963112 |
2018 |
|
rs2227982
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The haplotype analysis showed that the Ars10204525 Trs2227982 Crs7421861 haplotype was associated with a significantly decreased risk of breast cancer (OR = 0.50, 95% CI = 0.34-0.75).Our findings support an association between the PD-1 rs2227982 polymorphism and decreased breast cancer risk, especially in Her-2 positive breast cancer patients in the Chinese population.
|
27227944 |
2016 |
|
rs1058808
|
|
|
0.020 |
GeneticVariation |
BEFREE |
This study demonstrates that only the Ala1170Pro polymorphism is associated with prognostic factors in HER2-positive breast cancer patients.
|
27788409 |
2016 |